Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Comprehensive clinical development programs being initiated for each investigational candidate
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Subscribe To Our Newsletter & Stay Updated
